SHPH חוב כולל להון Shuttle Pharma

The historical debt-to-equity chart for Shuttle Pharmaceuticals (SHPH) is 0.01. The company's operations focus on developing agents in US laboratories that increase the radiosensitivity of head and neck neoplasms. Scaling prospects depend on integrating patented methods into global oncology practice, while the current stage is characterized by the expenditure of available funds on intensive scientific research.

This ratio determines the degree of financial leverage by comparing total liabilities to net assets to assess insolvency risks and capital structure efficiency. By analyzing the dynamics of equity dependence on debt via GURU.Markets, an investor can observe the balance of borrowed funds, which is critically important for Shuttle Pharmaceuticals (SHPH) during the development of innovative sensitizers for oncology.